Bildkälla: Stockfoto

Genovis: Strategic cross-licensing agreement - Redeye

In this note, Redeye elaborates on why we see the cross-licensing agreement with GlycoT Therapeutics as strategically interesting.

In this note, Redeye elaborates on why we see the cross-licensing agreement with GlycoT Therapeutics as strategically interesting.
Börsvärldens nyhetsbrev
ANNONSER